"Cade's disease" and beyond: Misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder

Canadian Journal of Psychiatry

Volumn 47, Issue 2, 2002, Pages 125-134

  Ghaemi, S Nassir ^a   Ko, James Y ^a   Goodwin, Frederick K ^a  

^a CAMBRIDGE HOSPITAL   (United States)

Author keywords

Antidepressants; Bipolar disorder; Diagnosis; Manic depressive illness; Mood stabilizers; Nosology; Treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; LITHIUM CARBONATE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ERROR; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; PSYCHIATRIC DIAGNOSIS; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

EID: 0036234164     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370204700202     Document Type: Review

References (59)

1. American biological psychiatry and psychopharmacology, 1944-1994
2. Shifts in diagnostic frequencies of schizophrenia and major affective disorders at six North American psychiatric hospitals, 1972-1988
3. The epidemiologic catchment area (ECA) program: Studying the prevalence and incidence of psychopathology
4. Affective disorders in 5 US communities
5. National Institute of Mental Health diagnostic interview
6. A comparison of clinical and diagnostic interview schedule diagnoses: Physician reexamination of lay-interviewed cases in the general population
7. "The problem of validity in field studies of psychological disorders" revisited
8. An overview of psychiatric disorders in America
9. Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania, depression, and surgical conditions
10. The National Depressive and Manic-depressive Association (NDMDA) survey of bipolar members
11. Neuropsychological aspects of lack of insight in bipolar disorder: A preliminary report
12. Diagnosing bipolar disorder and the effect of antidepressants: A naturalistic study
13. The prevalent clinical spectrum of bipolar disorders: Beyond DSM-IV
14. Classification of schizoaffective disorder
15. Insight in schizophrenia and mood disorders and its relation to psychopathology
16. Lack of insight in bipolar disorder: The acute manic episode
17. Awareness of illness in schizophrenia and schizoaffective and mood disorders
18. Prodromal and residual symptoms in bipolar I disorder
19. Cyclothymic disorder: Validating criteria for inclusion in the bipolar affective group
20. The evolving bipolar spectrum. Prototypes I, II, III and IV
21. The emerging epidemiology of hypomania and bipolar II disorder
22. A plea for the integrity of the bipolar concept
23. Information from relatives. Diagnosis of affective disorders
24. The spectrum of mania
25. Bipolar outcome in the course of depressive illness
26. Are there any differences between bipolar and unipolar melancholia?
27. The bipolar spectrum of depressions
28. Antidepressant-induced mania and cycle acceleration: A controversy revisited
29. Antidepressant-associated hypomania in outpatient depression: A 203-case study in private practice
30. Drug-induced switching in bipolar disorder
31. Switching from 'unipolar' to bipolar II. An 11-year prospective study of clinical and temperamental predictors in 559 patients
32. Systematic clinical methodology for validating bipolar-II disorder: Data in mid-stream from a French national multi-site study
33. Atypical and non-atypical subtypes of depression: Comparison of social functioning, symptoms, course of illness, co-morbidity, and demographic features
34. The clinical features of bipolar depression: A comparison with matched major depressive disorder patients
35. Reevaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders
36. The bipolar spectrum: A clinical reality in search of diagnostic criteria and an assessment methodology
37. Predictors of response to lithium augmentation in TCA-resistant depression
38. Loss of response to antidepressants and subsequent refractoriness: Diagnostic issues in a retrospective case series
39. Lithium carbonate and imipramine in prevention of affective episodes
40. Rapid cycling in manic-depressives induced by tricyclic antidepressants
41. Prophylactic lithium carbonate with and without imipramine for bipolar I patients
42. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: A prospective, placebo-controlled comparison
43. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: A report of the NIMH collaborative study group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination
44. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode
45. A double-blind trial of bupropion versus desiprimine for bipolar depression
46. Rapid cycling affective disorder: Contributing factors and treatment responses in 51 patients
47. Course of the manic-depressive cycle and changes caused by treatments
48. The role of antidepressant treatments in rapid-cycling
49. Rapid cyclers, temperament, and antidepressants
50. Long-term prognosis of bipolar I disorder
51. The expert consensus guideline series: Medication treatment of bipolar disorder
52. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: A retrospective chart review
53. An update on the Stanley Foundation Bipolar Network (SFBN)
54. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex versus lithium in the setting of minimal antidepressant use
55. An introduction to and history of affective disorders
56. The bipolar spectrum and the antidepressant view of the world
57. Efficacy and safety of antidepressants in long-term treatment of bipolar disorder